D
David L. Hess
Researcher at Oregon Health & Science University
Publications - 66
Citations - 6649
David L. Hess is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Testosterone & Luteal phase. The author has an hindex of 38, co-authored 63 publications receiving 6414 citations. Previous affiliations of David L. Hess include Oregon National Primate Research Center.
Papers
More filters
Journal ArticleDOI
Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
R. Bruce Montgomery,Elahe A. Mostaghel,Robert L. Vessella,David L. Hess,Thomas F. Kalhorn,Celestia S. Higano,Lawrence D. True,Peter S. Nelson,Peter S. Nelson +8 more
TL;DR: Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment.
Journal ArticleDOI
Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The atherosclerosis risk in communities (ARIC) study
Aaron R. Folsom,F. Javier Nieto,Paul G. McGovern,Michael Y. Tsai,M. Rene Malinow,John H. Eckfeldt,David L. Hess,Clarence E. Davis +7 more
TL;DR: The prospective findings add uncertainty to conclusions derived mostly from cross-sectional studies that tHcy is a major, independent, causative risk factor for CHD and point more strongly to the possibility that vitamin B6 offers independent protection.
Journal ArticleDOI
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer.
Elahe A. Mostaghel,Stephanie T. Page,Daniel W. Lin,Ladan Fazli,Ilsa Coleman,Lawrence D. True,Beatrice S. Knudsen,David L. Hess,Colleen C. Nelson,Alvin M. Matsumoto,William J. Bremner,Martin E. Gleave,Peter S. Nelson,Peter S. Nelson +13 more
TL;DR: Optimal clinical efficacy will require testing of novel approaches targeting complete suppression of systemic and intracrine contributions to the prostatic androgen microenvironment.
Journal ArticleDOI
Reduction of Plasma Homocyst(e)ine Levels by Breakfast Cereal Fortified with Folic Acid in Patients with Coronary Heart Disease
Manuel R. Malinow,Paul Barton Duell,David L. Hess,Peter H. Anderson,Warren D. Kruger,Beverley E. Phillipson,Beverley E. Phillipson,Robert A. Gluckman,Peter C. Block,Peter C. Block,Barbara M. Upson +10 more
TL;DR: Cereal fortified with folic acid has the potential to increase plasma folic Acid levels and reduce plasma homocyst(e)ine levels, and further clinical trials are required to determine whether folicacid fortification may prevent vascular disease.
Journal ArticleDOI
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Leonard S. Marks,Norman A. Mazer,Elahe A. Mostaghel,David L. Hess,Frederick Dorey,Jonathan I. Epstein,Robert W. Veltri,Danil V. Makarov,Alan W. Partin,David G. Bostwick,Maria Luz Macairan,Peter S. Nelson +11 more
TL;DR: Preliminary data suggest that in aging men with late-onset hypogonadism, 6 months of TRT normalizes serum androgens levels but appears to have little effect on prostate tissue androgen levels and cellular functions.